Apollomics (NASDAQ:APLM) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Apollomics (NASDAQ:APLM) from a sell rating to a hold rating in a research note published on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Apollomics in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Apollomics currently has an average rating of “Sell”.

Apollomics Stock Up 3.8%

Shares of Apollomics stock opened at $20.92 on Friday. Apollomics has a 1 year low of $3.66 and a 1 year high of $42.12. The stock has a fifty day moving average price of $17.97 and a 200-day moving average price of $13.80.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.